Capital Fund Management (CFM)
RETA

Capital Fund Management (CFM)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Capital Fund Management (CFM)’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,453
Closed -$381K – 1872
2021
Q4 		$381K Buy
+14,453
New +$1.12M ﹤0.01% 1493
2020
Q2 		– Sell
-8,966
Closed -$1.29M – 1681
2020
Q1 		$1.29M Buy
+8,966
New +$1.73M 0.02% 679

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capital Fund Management (CFM)'s RETA Position: Q1 2022 in Review

Capital Fund Management (CFM) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 14,453 shares — an estimated $381K sold.

Capital Fund Management (CFM) first reported a position in RETA in Q1 2020 and held it in 2 quarters. The position peaked at $1.29M in Q1 2020. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

  • Capital Fund Management (CFM) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 14,453 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $381K.
  • Capital Fund Management (CFM) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 2 quarters.
  • Capital Fund Management (CFM)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.29M in Q1 2020.
  • 149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2022, filed 12 May 2022.